. 2020 Nov 3;64(2):96–107. doi: 10.1111/idj.12087

Table 5.

Percentage, number and odds ratio of subjects who experienced adverse events

Adverse events	Studies included	Percentage and number of events in mepivacaine group %	Percentage and number of events in lidocaine group %	Odds ratio (95% CI)	P
Diplopia	Forloine²⁰	16 (8/50)	12 (6/50)	1.40 (0.45 4.37)	0.57
Increase in heart rate	Forloine²⁰	0 (0/50)	30 (15/50)	0.01 (0.00 0.09)	<0.0001
Increase in heart rate	Replogle²⁹	0 (0/42)	67 (28/42)	0.01 (0.00 0.09)	<0.0001
Mandibular lip numbness	Forloine²⁰	26 (13/50)	32 (16/50)	0.75 (0.31 1.78)	0.51
Incisive papilla swelling or soreness	Nusstein²⁸	20 (8/40)	28 (11/40)	0.66 (0.23 1.86)	0.43
Temporary anaesthesia/paraesthesia of incisive papilla	Nusstein²⁸	12 (5/40)	18 (7/40)	0.67 (0.19 2.33)	0.53
Thermal pulpal sensitivity	Nusstein²⁸	2 (1/40)	2 (1/40)	1.00 (0.06 16.56)	1.00
Ulcerations	Nusstein²⁸	5 (2/40)	0 (0/40)	5.26 (0.24 113.11)	0.29
Hyperaemia and soreness of injection site	Chen³¹	9 (1/11)	0 (0/7)	2.14 (0.08 60.17)	0.65
Dizzy and syncope	Shi³⁰	2 (1/66)	2 (1/61)	0.48 (0.09 2.66)	0.59
	Li³³	0 (0/35)	3 (1/35)
	He⁴⁰	0 (0/196)	1 (1/196)
Herpes-like lesions	Schleder¹⁶	3 (1/31)	10 (3/31)	0.31 (0.03 3.17)	0.32
Haematoma of interproximal papillae	Schleder¹⁶	3 (1/31)	0 (0/31)	3.10 (0.12 79.04)	0.49